Brokerages Set Coherus BioSciences, Inc. (CHRS) PT at $34.00
Coherus BioSciences, Inc. (NASDAQ:CHRS) has been given an average recommendation of “Buy” by the twelve analysts that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $32.89.
CHRS has been the topic of several research reports. BidaskClub lowered shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, August 15th. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $25.00 price target (down from $32.00) on shares of Coherus BioSciences in a report on Tuesday, August 8th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $17.00 price target (down from $24.00) on shares of Coherus BioSciences in a report on Wednesday, September 27th.
WARNING: “Brokerages Set Coherus BioSciences, Inc. (CHRS) PT at $34.00” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/09/brokerages-set-coherus-biosciences-inc-chrs-pt-at-34-00.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in Coherus BioSciences by 32.7% during the second quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,785 shares during the last quarter. Legal & General Group Plc raised its holdings in Coherus BioSciences by 12.6% during the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after buying an additional 1,046 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Coherus BioSciences during the second quarter worth $185,000. Boston Advisors LLC acquired a new position in Coherus BioSciences during the second quarter worth $244,000. Finally, Voya Investment Management LLC raised its holdings in Coherus BioSciences by 32.2% during the second quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock worth $253,000 after buying an additional 4,293 shares during the last quarter. Hedge funds and other institutional investors own 78.12% of the company’s stock.
Shares of Coherus BioSciences (NASDAQ:CHRS) traded down $0.45 during trading on Monday, reaching $10.60. 347,217 shares of the company’s stock traded hands, compared to its average volume of 599,640. The company has a quick ratio of 4.27, a current ratio of 5.46 and a debt-to-equity ratio of 1.84. Coherus BioSciences has a twelve month low of $10.07 and a twelve month high of $29.59.
Coherus BioSciences (NASDAQ:CHRS) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.26). Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 582.31%. equities research analysts expect that Coherus BioSciences will post -4.34 EPS for the current fiscal year.
About Coherus BioSciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Stock Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related stocks with our FREE daily email newsletter.